greeksoup/ stock research
Stock research / United States / ARWR / Planned sales

Arrowhead Pharmaceuticals, Inc. planned insider sales

In the twelve months since 9 October 2025 insiders at Arrowhead Pharmaceuticals, Inc. filed 21 Form 144 notices of planned sales, 560,065 shares worth $37.3 million at the time of filing, from 10 sellers. The latest, filed 18 August 2026: Adeoye Olukotun (director), 2,000 shares worth $173,876, planned for around 18 August 2026 through Merrill Lynch.

FiledSellerRelationshipSharesValuePlanned saleBrokerHow acquiredFiling
18 August 2026Adeoye OlukotunDirector2,000$173,87618 August 2026Merrill LynchCompensationForm 144
18 August 2026Michael PerryDirector11,600$1.0 million18 August 2026Merrill LynchCompensationForm 144
12 May 2026Hongbo LuOfficer2,970$228,29912 May 2026Merrill LynchCompensationForm 144
23 April 2026James HamiltonOfficer10,000$749,99823 April 2026Merrill LynchCompensationForm 144
22 April 2026Daniel ApelOfficer13,095$934,20622 April 2026Merrill LynchBonusForm 144
5 March 2026James HamiltonOfficer10,000$641,8705 March 2026Merrill LynchCompensationForm 144
5 January 2026James HamiltonOfficer39,728$2.5 million5 January 2026Merrill LynchCompensationForm 144
5 January 2026Patrick O'BrienOfficer49,493$3.1 million5 January 2026Merrill LynchCompensationForm 144
2 January 2026Christopher AnzaloneOfficer13,187$871,6682 January 2026Merrill LynchCompensationForm 144
29 December 2025Mauro FerrariDirector7,530$527,07026 December 2025Merrill LynchCompensationForm 144
29 December 2025Christopher AnzaloneOfficer51,726$3.6 million29 December 2025Merrill LynchCompensationForm 144
22 December 2025Christopher AnzaloneOfficer12,586$861,31922 December 2025Merrill LynchCompensationForm 144
19 December 2025William WaddillDirector8,367$566,00119 December 2025Merrill LynchCompensationForm 144
19 December 2025Adeoye OlukotunDirector10,000$676,58919 December 2025Merrill LynchCompensationForm 144
19 December 2025Victoria VakienerDirector10,040$679,46419 December 2025Merrill LynchCompensationForm 144
19 December 2025Christopher AnzaloneOfficer13,445$909,63219 December 2025Merrill LynchCompensationForm 144
17 December 2025Christopher AnzaloneOfficer85,000$5.4 million17 December 2025Merrill LynchCompensationForm 144
16 December 2025Christopher AnzaloneOfficer54,298$3.4 million16 December 2025Merrill LynchCompensationForm 144
15 December 2025Christopher AnzaloneOfficer130,000$9.0 million15 December 2025Merrill LynchCompensationForm 144
5 December 2025Michael PerryDirector16,250$991,1295 December 2025Merrill LynchCOMPENSATIONForm 144
28 November 2025Mauro FerrariDirector8,750$493,06228 November 2025Merrill LynchCompensationForm 144
A Form 144 is the notice an insider files with the SEC before selling restricted or control shares over the Rule 144 thresholds; it says what may be sold, not what was.
Read moreValue is the filer's own aggregate market value. Whether the sale happened shows up later on Form 4, on the insiders page.

Source

Form 144 filings on EDGAR for Arrowhead Pharmaceuticals, Inc.: the company's filing index, each notice read from its own XML.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install